Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corp executive vice president reports small share transfer
Chemed Corp executive vice president Spencer S. Lee reported a change in ownership of company stock. On 11/19/2025, Lee disposed of 60 shares of Chemed Corp capital stock in a transaction coded "G," which typically denotes a gift or similar transfer, at a reported price of $0.00 per share. After this transaction, Lee beneficially owns 14,567 shares directly.
Chemed (CHE) reported Q3 2025 results. Service revenues and sales were $624.9 million, up from $606.2 million a year ago. Net income was $64.2 million versus $75.8 million, and diluted EPS was $4.46 compared with $5.00. Segment revenue was $407.7 million at VITAS and $217.2 million at Roto‑Rooter.
For the first nine months, revenue reached $1.89 billion (vs. $1.79 billion) with net income of $188.5 million (vs. $211.7 million). Cash from operations was $254.7 million, supporting $253.5 million of share repurchases year‑to‑date, including $180.8 million in Q3. Cash was $129.8 million, and approximately $404.5 million remained available under the revolving credit facility. The company paid a $0.60 per share dividend in Q3; shares outstanding were 14,164,195 as of September 30, 2025. In VITAS, an Administrative Law Judge largely upheld higher‑level‑of‑care billings; the Medicare Administrative Contractor refunded the previously deposited amount, reducing the overpayment to a de minimis figure. Board repurchase authorization remaining was $301.8 million.
Chemed Corporation filed a current report stating that on October 28, 2025 it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company notes that this press release is furnished as Exhibit 99 to the report, making the detailed quarterly results available through that exhibit.
Chemed Corp (CHE) reported an insider equity award on Form 4. Joel L. Wherley, CEO of VITAS Healthcare, received a stock option grant covering 17,476 shares at an exercise price of $443.79 on 10/21/2025.
The options vest in three equal annual installments commencing 10/21/2026 and expire on 10/21/2030. Following the transaction, Wherley beneficially owned 32,819 derivative securities directly. No non-derivative share transactions were reported in Table I.
Chemed Corp (CHE) executive vice president Spencer S. Lee reported a stock option grant. On 10/21/2025, he received 12,759 stock options with an exercise price of $443.79 per share, expiring on 10/21/2030. The options vest in three equal annual installments beginning 10/21/2026. Following this grant, he beneficially owned 28,196 derivative securities, held directly.
Chemed Corp (CHE) reported an insider equity award. On 10/21/2025, the company granted its VP and Chief Legal Officer a stock option for 15,017 shares at an exercise price of $443.79 per share, expiring on 10/21/2030. The option vests in three equal annual installments commencing 10/21/2026. After this grant, the reporting person beneficially owned 38,067 derivative securities, held directly.
Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025. Each option has an exercise price of $443.79 and is a right to buy capital stock, expiring on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following this transaction, the reporting person beneficially owned 53,970 derivative securities, held in Direct ownership form.
Chemed Corp (CHE) reported an insider equity award. Director and vice president Thomas C. Hutton filed a Form 4 showing a grant of 6,338 stock options on 10/21/2025, with an exercise price of $443.79 per share. The options relate to Chemed capital stock and expire on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following the reported transaction, Hutton beneficially owned 26,718 derivative securities. Ownership is reported as direct.
Chemed Corp (CHE) reported an insider equity award. CEO and Director Kevin J. McNamara received a grant of stock options covering 58,672 shares on 10/21/2025, with an exercise price of $443.79 per share. The options expire on 10/21/2030 and vest in three equal annual installments starting 10/21/2026. Following this award, he directly holds 266,159 derivative securities. No non-derivative transactions were listed in the excerpt.
Kevin J. McNamara, President, CEO and a director of Chemed Corporation (CHE), reported an open-market sale of 3,000 shares of Chemed common stock on 09/26/2025. The reported weighted-average sale price was $461.28 per share (transactions ranged from $460.03 to $462.44). After the sale the reporting person beneficially owned 96,197 shares. The Form 4 includes an offer to provide transaction-level price/volume details on request.